BBIO - BridgeBio Pharma granted FDA review for amyloidosis therapy
2024-02-05 07:56:15 ET
More on BridgeBio Pharma
- BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
- BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
- BridgeBio Pharma: Taking Some Profits
- BridgeBio Pharma inks royalty deal for lead drug
- BridgeBio Phase 3 data for ATTR-CM drug published in NEJM